New blood test could personalize AML treatment
NCT ID NCT07060001
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new blood test (5hmC) to see if it can help doctors choose between two standard treatments for acute myeloid leukemia (AML): a milder drug (hypomethylating agent) or strong chemotherapy. About 112 newly diagnosed adults will have their blood tested after initial treatment to check for leftover cancer cells. The goal is to see if using this test leads to better remission rates and longer survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hypomethylating agent (HMA) and intensive chemotherapy
What this could lead to
If successful, this blood test could help doctors choose the most effective treatment for each AML patient, potentially improving remission rates and survival.
What could go wrong
This is a Phase 2 trial with only 112 participants, so results may not apply to all AML patients. The test is new and may not be more accurate than current methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••